OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer
OSR Holdings (NASDAQ: OSRH) has appointed Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer brings over 20 years of experience in drug development, specializing in oncology and immunology. She previously held leadership positions at Merck Healthcare, where she led global programs from preclinical to late-stage clinical development.
Dr. Höfer's extensive background includes senior roles at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, where she advanced therapeutic programs across various modalities including NBEs, NCEs, nucleotides, and viral and cell-based therapies. She holds a PhD in Pharmacology from the University of Newcastle and has expertise in clinical pharmacology and translational medicine.
The appointment aims to strengthen OSR Holdings' R&D capabilities and accelerate the development of breakthrough therapies. Dr. Höfer will oversee the company's scientific strategy, innovation pipeline, and focus on expanding its footprint in oncology and immunology.
OSR Holdings (NASDAQ: OSRH) ha nominato la Dr.ssa Constance Höfer come nuovo Chief Scientific Officer (CSO). La Dr.ssa Höfer porta con sé oltre 20 anni di esperienza nello sviluppo di farmaci, specializzandosi in oncologia e immunologia. In precedenza ha ricoperto ruoli di leadership presso Merck Healthcare, dove ha guidato programmi globali dallo sviluppo preclinico a quello clinico avanzato.
Il vasto background della Dr.ssa Höfer include ruoli senior presso Sandoz Biopharmaceuticals, Priaxon AG e Medigene AG, dove ha avanzato programmi terapeutici attraverso varie modalità, tra cui NBEs, NCEs, nucleotidi e terapie virali e cellulari. Ha conseguito un dottorato in farmacologia presso l'Università di Newcastle e ha competenze in farmacologia clinica e medicina traslazionale.
La nomina mira a rafforzare le capacità di R&S di OSR Holdings e ad accelerare lo sviluppo di terapie innovative. La Dr.ssa Höfer supervisionerà la strategia scientifica dell'azienda, il pipeline di innovazione e si concentrerà sull'espansione della sua presenza in oncologia e immunologia.
OSR Holdings (NASDAQ: OSRH) ha nombrado a la Dra. Constance Höfer como su nueva Directora Científica (CSO). La Dra. Höfer aporta más de 20 años de experiencia en el desarrollo de medicamentos, especializándose en oncología e inmunología. Anteriormente ocupó puestos de liderazgo en Merck Healthcare, donde lideró programas globales desde el desarrollo preclínico hasta el clínico avanzado.
El extenso historial de la Dra. Höfer incluye roles séniores en Sandoz Biopharmaceuticals, Priaxon AG y Medigene AG, donde avanzó programas terapéuticos en diversas modalidades, incluidas NBEs, NCEs, nucleótidos y terapias virales y celulares. Tiene un doctorado en farmacología de la Universidad de Newcastle y cuenta con experiencia en farmacología clínica y medicina traslacional.
La designación tiene como objetivo fortalecer las capacidades de I+D de OSR Holdings y acelerar el desarrollo de terapias innovadoras. La Dra. Höfer supervisará la estrategia científica de la empresa, el pipeline de innovación y se centrará en expandir su presencia en oncología e inmunología.
OSR Holdings (NASDAQ: OSRH)는 Dr. Constance Höfer를 새로운 최고 과학 책임자 (CSO)로 임명했습니다. Höfer 박사는 종양학 및 면역학을 전문으로 하여 20년 이상의 약물 개발 경험을 보유하고 있습니다. 그녀는 이전에 Merck Healthcare에서 리더십 직책을 맡아 임상 전 단계부터 후기 임상 개발까지의 글로벌 프로그램을 이끌었습니다.
Höfer 박사의 광범위한 배경에는 Sandoz Biopharmaceuticals, Priaxon AG 및 Medigene AG에서의 고위직이 포함되어 있으며, 여기서 NBEs, NCEs, 뉴클레오타이드, 바이러스 및 세포 기반 치료를 포함한 다양한 방식의 치료 프로그램을 발전시켰습니다. 그녀는 뉴캐슬 대학교에서 약리학 박사 학위를 받았으며, 임상 약리학 및 전이 의학에 대한 전문성을 가지고 있습니다.
이번 임명은 OSR Holdings의 연구 개발 능력을 강화하고 혁신적인 치료법 개발을 가속화하는 것을 목표로 하고 있습니다. Höfer 박사는 회사의 과학 전략, 혁신 파이프라인을 감독하고 종양학 및 면역학 분야에서의 입지를 확장하는 데 집중할 것입니다.
OSR Holdings (NASDAQ: OSRH) a nommé Dr. Constance Höfer comme nouveau Directeur Scientifique (CSO). Dr. Höfer apporte plus de 20 ans d'expérience dans le développement de médicaments, en se spécialisant en oncologie et en immunologie. Auparavant, elle a occupé des postes de direction chez Merck Healthcare, où elle a dirigé des programmes mondiaux du développement préclinique à la fin de la phase clinique.
Le parcours étendu de Dr. Höfer comprend des postes de haut niveau chez Sandoz Biopharmaceuticals, Priaxon AG et Medigene AG, où elle a fait progresser des programmes thérapeutiques dans diverses modalités, y compris les NBEs, les NCEs, les nucléotides et les thérapies virales et cellulaires. Elle détient un doctorat en pharmacologie de l'Université de Newcastle et possède une expertise en pharmacologie clinique et en médecine translationnelle.
Cette nomination vise à renforcer les capacités de R&D d'OSR Holdings et à accélérer le développement de thérapies innovantes. Dr. Höfer supervisera la stratégie scientifique de l'entreprise, le pipeline d'innovation et se concentrera sur l'expansion de sa présence en oncologie et immunologie.
OSR Holdings (NASDAQ: OSRH) hat Dr. Constance Höfer zur neuen Chief Scientific Officer (CSO) ernannt. Dr. Höfer bringt über 20 Jahre Erfahrung in der Arzneimittelentwicklung mit, spezialisiert auf Onkologie und Immunologie. Zuvor hatte sie Führungspositionen bei Merck Healthcare inne, wo sie globale Programme von der präklinischen bis zur späten klinischen Entwicklung leitete.
Dr. Höfers umfangreicher Hintergrund umfasst leitende Positionen bei Sandoz Biopharmaceuticals, Priaxon AG und Medigene AG, wo sie therapeutische Programme in verschiedenen Modalitäten, einschließlich NBEs, NCEs, Nukleotide und virale sowie zellbasierte Therapien, vorantrieb. Sie hat einen Doktortitel in Pharmakologie von der Universität Newcastle und verfügt über Fachkenntnisse in klinischer Pharmakologie und translationaler Medizin.
Die Ernennung zielt darauf ab, die F&E-Kapazitäten von OSR Holdings zu stärken und die Entwicklung bahnbrechender Therapien zu beschleunigen. Dr. Höfer wird die wissenschaftliche Strategie des Unternehmens, die Innovationspipeline überwachen und sich auf die Erweiterung seiner Präsenz in der Onkologie und Immunologie konzentrieren.
- Appointment of highly experienced CSO with 20+ years in drug development
- Strong expertise in multiple therapeutic modalities and development stages
- Enhanced R&D leadership in oncology and immunology sectors
- Potential for improved clinical development and regulatory success rates
- None.
Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs across various modalities, including New Biological Entities (NBEs), New Chemical Entities (NCEs), nucleotides, and viral and cell-based therapies.
Regarding her new appointment, Dr. Höfer said "I am honored to join the distinguished team at OSR Holdings and eager to leverage my extensive drug development experience to advance novel therapies across multiple modalities and therapeutic areas. I look forward to collaborating with my colleagues to improve the lives of patients."
Coupled with her extensive industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has a strong foundation in clinical pharmacology and translational medicine, ensuring a seamless transition from early-stage research to successful clinical development.
"We are thrilled to welcome Constance to OSR Holdings. Her depth of experience and proven leadership in drug development will be instrumental in driving our scientific strategy forward," said Kuk Hyoun Hwang, CEO of OSR Holdings. "With her deep understanding of preclinical-to-clinical transition strategies and regulatory pathways, she will play a pivotal role in optimizing our pipeline and accelerating the development of breakthrough therapies for patients worldwide."
Dr. Höfer's appointment reinforces OSR Holdings' commitment to advancing cutting-edge therapeutic solutions and strengthening its R&D capabilities. Her expertise will enhance the company's ability to identify and develop promising drug candidates, streamline clinical development, and improve regulatory success rates. By leveraging her experience in biologics, small molecules, and other advanced therapeutic modalities, OSR Holdings aims to accelerate the translation of innovative research into clinical applications, expand its footprint in oncology and immunology, and drive long-term value for both patients and stakeholders.
About OSR Holdings, Inc.
OSR Holdings, Inc. (OSR) is a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. OSR aims to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. Its current operating businesses (through three wholly owned subsidiaries) include (i) developing oral immunotherapies for the treatment of cancer, (ii) developing design-augmented biologics for age-related and other degenerative diseases and (iii) neurovascular intervention medical device and systems distribution in
Contact
Email: ir@osr-holdings.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/osr-holdings-appoints-dr-constance-hofer-as-chief-scientific-officer-302410052.html
SOURCE OSR Holdings Inc.
FAQ
What experience does Dr. Constance Höfer bring to OSRH as the new CSO?
How will Dr. Höfer's appointment impact OSRH's drug development pipeline?
What therapeutic areas will OSRH focus on under Dr. Höfer's leadership?
What are Dr. Höfer's key responsibilities as OSRH's new Chief Scientific Officer?
